Chemoresistance in Breast Cancer Patients Associated With Changes in P2X7 and A2A Purinergic Receptors in CD8+ T Lymphocytes

• Ngā kaituhi matua: Victor Manuel Ruiz-Rodríguez (Author), Eneida Turiján-Espinoza (Author), Jaime Arturo Guel-Pañola (Author), Mariana Haydee García-Hernández (Author), José de Jesús Zermeño-Nava (Author), Nallely López-López (Author), Sofia Bernal-Silva (Author), Esther Layseca-Espinosa (Author), Ezequiel M. Fuentes-Pananá (Author), Ana María Estrada-Sánchez (Author), Diana Patricia Portales-Pérez (Author)
• Hōputu: Pukapuka
• I whakaputaina: Frontiers Media S.A., 2020-11-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Breast cancer (BRCA) is the most frequent cancer type that afflicts women. Unfortunately, despite all the current therapeutic strategies, many patients develop chemoresistance hampering the efficacy of treatment. Hence, an early indicator of therapy efficacy might aid in the search for better treatm...